☆ 4.6 Letter

Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Get Full Text
Add to Collection

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume 189, Issue 3, Pages E86-E90

Publisher

WILEY
DOI: 10.1111/bjh.16499

Keywords

Hodgkin lymphoma; first salvage therapy; autologous stem cell transplantation; brentuximab vedotin; bendamustine

Categories

Hematology

Funding

  1. Seattle Genetics, Inc.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.